Fecha de recepción: 24/02/2018 – Fecha de aceptación: 25/04/2018
Navacerrada Cabrero MI1, Sánchez Cuervo M1, Marquet Palomanes J2, Delgado Silveira E1
1 Servicio de Farmacia
2 Servicio de Hematología
Hospital Universitario Ramón y Cajal. Madrid (España)
____
Correspondencia:
María Isabel Navacerrada Cabrero
Hospital Universitario Ramón y Cajal
(Servicio de Farmacia)
Ctra. Colmenar Viejo km. 9, 100
28034 Madrid
Correo electrónico: mariaisabel.navacerrada@salud.madrid.org
____
SUMMARY
Patient admitted to the emergency department of a tertiary hospital, anticoagulated with dabigatran that presents an episode of severe pulmonary bleeding.
The main purpose of the study is the pharmacodynamic assessment of idarucizumab to neutralize the anticoagulant activity of dabigatran. The main purpose of the study is the pharmacodynamic assessment of idarucizumab to neutralize the anticoagulant activity of dabigatran with a good safety profile.
The recommended dose of idarucizumab 5 g/vial in vulnerable patients may be above the dose necessary to achieve the therapeutic effect for sustained reversion of dabigatran.
This case and other published cases suggest that the dose should be individualized according to the characteristics of the patient or monitor plasma levels to adjust the dose to the effective therapeutic need of the anticoagulant effect in each patient.
Key Words: Dabigatran, NACO, reversion, idarucizumab.
____